Retatrutide

Mechanism of action

Combined receptor agonism: - GLP-1R: increases glucose-dependent insulin secretion, reduces glucagon secretion under hyperglycemic conditions, slows gastric emptying, and increases satiety via hypothalamic and brainstem circuits. - GIPR: modulates insulin secretion and may influence energy balance and adipocyte response; in combination with GLP-1R it may enhance weight loss and tolerability in some contexts. - GCGR (glucagon receptor): increases hepatic glucose production and fat lipolysis/oxidation, and may increase energy expenditure; the concomitant incretin action tends to counterbalance the risk of hyperglycemia. Downstream effects: reduced appetite and caloric intake, possible increase in thermogenesis/energy expenditure, improved insulin sensitivity, and reduction in triglycerides and steatosis markers in some studies.

Supported benefits

• Reduction in body weight in subjects with obesity (high average weight loss versus placebo in phase 2 studies) (strong)
• Improvement in glycemic parameters (e.g. HbA1c and blood glucose) in populations with metabolic dysfunction/diabetes in clinical studies (moderate)
• Improvement in cardiometabolic markers (triglycerides, blood pressure, waist circumference) and indicators of hepatic steatosis in subgroups/exploratory analyses (moderate)
• Possible increase in energy expenditure/lipid oxidation compared with pure incretin agonists (a hypothesis consistent with glucagon agonism, but not always directly quantified in clinical endpoints) (emerging)

Safety & side effects

• Gastrointestinal (very common and dose-dependent): nausea, vomiting, diarrhea, constipation, abdominal pain, dyspepsia
• Marked reduction in appetite (may lead to insufficient energy/protein intake)
• Injection-site reactions (erythema, pain, itching)
• Possible increase in heart rate (observed with some incretin agonists; should be monitored in trials)
• Possible gallbladder alterations (e.g. gallstones/cholecystitis) associated with rapid weight loss and/or the incretin class
• Rare but relevant: pancreatitis (a class association under discussion; requires clinical attention), dehydration/electrolyte disturbances secondary to vomiting/diarrhea

FAQ

What is a GIP/GLP-1/glucagon tri-agonist and why is it different from a GLP-1 agonist?

A GLP-1 agonist acts mainly on satiety, gastric emptying, and glucose-dependent insulin secretion. A tri-agonist adds activation of GIPR and the glucagon receptor: in theory it can amplify weight loss and influence energy expenditure, but it can also alter the tolerability profile and requires specific safety assessments.

Is retatrutide a weight-loss supplement?

No. It is an experimental pharmacological peptide studied in clinical trials. It does not fall into the category of supplements and should not be purchased or used outside regulated clinical pathways.

What are the most common side effects observed in studies?

Predominantly gastrointestinal (nausea, vomiting, diarrhea or constipation, abdominal pain), often dose-dependent. Injection-site reactions and, in some cases, changes in heart rate have also been reported.

Why is dose titration used in trials?

To reduce the intensity and frequency of gastrointestinal adverse effects, improving tolerability and adherence. Titration schedules vary between protocols.

Can it affect the absorption of oral medications?

Yes, indirectly: by slowing gastric emptying it can alter the absorption kinetics of some drugs. This is particularly relevant for medications with a narrow therapeutic window and requires clinical evaluation.